European Commission Approval and Market Entry
Sandoz Group AG has announced that its ranibizumab biosimilar, Ranoluspec, will be commercially available across the European Union (except Germany) on 12 November 2026. The product received full approval from the European Commission in February 2026, following a comprehensive assessment of analytical, pre‑clinical, and clinical data that demonstrated equivalence to the reference biologic in terms of safety, purity, potency, and efficacy.
The approval was granted under the European Medicines Agency’s (EMA) biosimilar pathway, which requires rigorous comparability studies to establish that any differences between the biosimilar and the originator are not clinically meaningful. For Ranluspec, these studies included:
| Study Type | Key Findings |
|---|---|
| Analytical Characterisation | Full similarity in primary structure, post‑translational modifications, higher‑order structure, and glycosylation patterns. |
| In‑vitro Functional Assays | Comparable binding affinity to VEGF‑A, identical potency in endothelial cell proliferation and tube‑formation assays. |
| Pharmacokinetics in Healthy Volunteers | Linear, dose‑proportional exposure with no significant differences in Cmax or AUC compared to reference. |
| Phase III Efficacy Trial (N=1,200) | Non‑inferiority margin of 5 % in best‑corrected visual acuity gain at 52 weeks, identical safety profile, and comparable rates of ocular adverse events. |
These data underpin the EMA’s confidence that Ranluspec will deliver therapeutic outcomes equivalent to the brand‑name ranibizumab while providing a cost‑effective alternative for patients and payers.
Clinical Indications and Therapeutic Rationale
Ranoluspec is indicated for the treatment of neovascular (“wet”) age‑related macular degeneration (AMD), diabetic macular oedema (DME), and retinal vein‑occlusion‑associated oedema (RVO‑O). All three conditions share a common pathogenic driver: aberrant vascular endothelial growth factor A (VEGF‑A) signalling, which promotes pathological neovascularisation and increased vascular permeability.
Mechanistic Overview
- VEGF‑A Binding – Ranluspec’s Fab fragment competitively binds VEGF‑A isoforms (e.g., VEGF‑121, VEGF‑165), preventing interaction with VEGF receptor‑2 (VEGFR‑2) on endothelial cells.
- Signal Inhibition – This blockade attenuates downstream phosphorylation cascades (PLC‑γ, PI3K/AKT, MAPK) that normally lead to endothelial proliferation, migration, and survival.
- Barrier Restoration – By reducing VEGF‑A‑mediated disruption of tight‑junction proteins, Ranluspec restores retinal‑vascular barrier integrity, decreasing oedema.
- Angiogenesis Suppression – Long‑term inhibition of VEGF‑A activity halts the growth of abnormal choroidal vessels characteristic of wet AMD and neovascular DME.
The pharmacokinetic profile of ranibizumab—rapid systemic clearance and a half‑life of ~7–8 days in ocular tissues—ensures that dosing intervals can be spaced 4–6 weeks without loss of efficacy, aligning with current clinical practice.
Market Dynamics and Regulatory Strategy
Pricing and Access
The introduction of Ranluspec is projected to reduce the cost of intravitreal ranibizumab therapy by 20–30 %, depending on regional reimbursement negotiations. This pricing strategy is expected to:
- Increase Treatment Uptake – Lower out‑of‑pocket expenses for patients, especially in countries with cost‑sharing schemes.
- Improve Budget Impact – Reduce overall expenditure for national health systems by offering a cheaper alternative to branded ranibizumab and other anti‑VEGF agents such as aflibercept and bevacizumab.
Sandoz’s partnership with Lupin Limited for manufacturing, registration, and marketing across the EU (excluding Germany) leverages Lupin’s established supply chain and regulatory expertise, expediting market penetration. In Germany, a separate agreement supplies a different ranibizumab biosimilar, reflecting Germany’s unique reimbursement and competition frameworks.
Bio100 Portfolio Expansion
Ranoluspec launch aligns with Sandoz’s Bio100 strategy, which aims to catalogue over 100 biosimilar products by 2040. The focus on high‑impact therapeutic areas—particularly ophthalmology—serves multiple strategic objectives:
- Portfolio Diversification – Reduces dependence on a narrow range of therapeutic classes.
- Market Leadership – Positions Sandoz as the principal provider of affordable anti‑VEGF therapies in the EU.
- Regulatory Momentum – Builds on previous successful launches of aflibercept and ranibizumab biosimilars, creating a robust pipeline for future approvals.
The company’s 2025 sales figure of USD 11.1 billion, coupled with a longstanding reputation for affordable medicines, provides the financial capital and market credibility to capture significant market share within the competitive biosimilars segment.
Conclusion
The European launch of Ranluspec represents a scientifically sound and commercially strategic expansion of Sandoz’s biosimilar portfolio. With rigorous evidence of clinical equivalence to reference ranibizumab and a clear therapeutic mechanism targeting VEGF‑A, the biosimilar is poised to enhance patient access to effective retinal disease therapies while supporting the sustainability of European healthcare systems. The partnership with Lupin Limited and the broader Bio100 strategy further solidify Sandoz’s leadership position in the rapidly evolving biosimilars market.
